Beth Seidenberg, a longtime life sciences investor, brings her medical expertise in the venture capital world to Capsida’s Board of Directors. Dr. Seidenberg has built more than 35 successful biotechnology companies over the past 15 years, including ARMO, Arresto, Arsenal Biosciences, Atara Biotherapeutics, Cell Design Labs, Epizyme, Flexus, iPierian, Kyverna Therapeutics, Neuron23, TESARO, RAPT, Tmunity, True North, Livongo and Progeny. She currently serves as Founding Managing Director of Westlake Village BioPartners and a general partner at Kleiner Perkins, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients. In addition to her time in life science investing, Dr. Seidenberg has significant senior-level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories. Dr. Seidenberg’s impact has been recognized across the industry. She was recently named by Barron’s as one of the 100 most influential women in U.S. finance and was named to the 2020 Forbes Midas List as a top tech investor.
Dr. Seidenberg holds an M.D. from University of Miami Leonard M. Miller School of Medicine and a B.S. from Barnard College. She conducted her post-graduate training at The National Institutes of Health and Johns Hopkins University School of Medicine.